Rhumbline Advisers Maxcyte, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Maxcyte, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 150,460 shares of MXCT stock, worth $255,782. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150,460
Previous 153,034
1.68%
Holding current value
$255,782
Previous $417,000
21.34%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding MXCT
# of Institutions
122Shares Held
71.2MCall Options Held
0Put Options Held
0-
Cadian Capital Management, LP New York, NY8.91MShares$15.2 Million1.1% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$13.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY7.03MShares$11.9 Million0.0% of portfolio
-
Mirabella Financial Services LLP London, X06.6MShares$11.2 Million1.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$9.52 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $173M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...